Delving into the Latest Updates on Nifuroxazide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Nifuroxazide (INN)

+ [1]

Target-

Action-

Mechanism-

Therapeutic Areas

Digestive System DisordersOther Diseases

Active Indication

ColitisDiarrhea

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC12H9N3O5

InChIKeyYCWSUKQGVSGXJO-UHFFFAOYSA-N

CAS Registry965-52-6

Ulcerative colitis (UC) is one of the most common types of chronic and non-specific inflammatory bowel diseases (IBD). It is characterized by cytokine-induced continuous and diffuse inflammatory infiltrations into the rectum's mucosa and extends proximally to the colon. Patients with UC predominantly have bloody diarrhea, abdominal pain, fecal urgency, and tenesmus, which extremely alters their quality of life.
Although the precise pathological mechanism of UC remains unclear, several studies have been outlined many factors that could involve in the pathogenesis of UC, including, but not limited to, initiation of the inflammatory response, disruption of oxidant/antioxidant status, dysregulation of the immune response, alteration of gut microbiota, and delaying epithelial barrier healing. Loss of intestinal barrier function and dysregulated immune response are the key events during colitis development

Start Date20 Aug 2023

Sponsor / Collaborator

Tanta University

NCT05754996

/ RecruitingPhase 3IIT

Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis

Evaluating the efficacy and safety of the efficacy and safety of nifuroxazide in the treatment of hepatic encephalopathy in patients with grade II-III hepatic encephalopathy

Start Date12 Mar 2023

Sponsor / Collaborator

Cairo University

100 Clinical Results associated with Nifuroxazide

Login to view more data

100 Translational Medicine associated with Nifuroxazide

Login to view more data

100 Patents (Medical) associated with Nifuroxazide

Login to view more data

382

Literatures (Medical) associated with Nifuroxazide

01 May 2025·International Journal of Biological Macromolecules

Time-series RNA sequencing reveals that immulectin-1 (IML-1) is a potential target for biological control of fall armyworm, Spodoptera frugiperda

Article

Author: Liu, Feng ; Liang, Chao-Peng ; Liu, Fang-Fang ; Ren, Hai-Yan ; Qi, Wen-Xuan ; Zhang, Bang-Xian ; Rao, Xiang-Jun

Insects mount robust immune responses to reduce the efficacy of biopesticides. Identification of critical immune targets for biocontrol strategies is thus essential. However, immune targets in the fall armyworm, Spodoptera frugiperda (Lepidoptera: Noctuidae), a major pest of corn, remain largely unexplored. Here, we investigated the immune response of S. frugiperda to the entomopathogen Beauveria bassiana (Hypocreales: Cordycipitaceae). Time-series RNA sequencing revealed 863, 717, and 165 differentially expressed genes (DEGs) at 24, 48, and 60 h post-infection, respectively. GO and KEGG enrichment analyses revealed that DEGs were significantly enriched in immune-related terms and pathways. Among the DEGs, the gene encoding immulectin SfIML-1, a C-type lectin with dual carbohydrate recognition domains, was significantly upregulated during the early and intermediate stages of infection. Genome-wide analysis identified nine IML genes, with SfIML-1 as the only one highly responsive to B. bassiana. Recombinant SfIML-1 binds pathogen-associated molecular patterns and pathogens, enhancing cellular responses. RNAi of SfIML-1 decreased survival after fungal infection, while injection of recombinant SfIML-1 increased survival. Suppression of the NF-κB and JAK-STAT pathways diminished SfIML-1 expression in both fat body and Sf9 cells. These results identify SfIML-1 as a key pattern recognition receptor and a promising target for developing novel biocontrol strategies.

01 Apr 2025·European Journal of Medicinal Chemistry

The assembled decoders to prepare for “bioactive X″ against progressive deterioration of liver disease: From NAFLD to HCC

Article

Author: Kim, Dong Joon ; Suk, Ki-Tae ; Lee, Kyeong Jin ; Kwon, Goo-Hyun ; Oh, Ki-Kwang ; Eom, Jung-A ; Yoon, Sang-Jun

Non-alcoholic fatty liver disease (NAFLD) is implicated in steatohepatitis (NASH), liver cirrhosis (LC) to hepatocellular carcinoma (HCC), sequentially. Herein, our aim was to unravel the nuanced key components (compounds, and targets) to deter the progressive severity concerning hepatocellular diseases. We incorporated rigor bioinformatics and computational screening tools to decode effector(s) against NAFLD, NASH, LC, and HCC. The corresponding ligands of PDX1 (transcription factor of INS; one agonist), and IL6 (thirty-two antagonists) were identified by Selleckchem. Molecular docking test (MDT) revealed that PDX1- BRD7552 conformer (-12.1 kcal/mol), and IL6- Forsythoside B (-11.4 kcal/mol) conformer formed most stable complex. In parallel, DFT proposed that BRD7552, and Forsythoside B had significant chemical properties to react the targets, respectively. In conclusion, we decoded causatives of the progressive liver disease with web-based tools in drug repositioning theory. BRD7552 as PDX1 agonist, and Forsythoside B as IL6 antagonist were attributed to synergistic efficacy against NAFLD-derived HCC.

01 Feb 2025·Brain Research Bulletin

JAK/STAT3 signaling promotes pain and depression-like behaviors in rats with bone cancer pain by regulating Th17 cell differentiation

Article

Author: Chen, Xiaohui ; Wu, Shuyan ; Zheng, Xiaochun ; Wang, Ying ; Lin, Daoyi ; Chen, Jianghu ; Lin, Mingxue ; Chen, Pinzhong ; Jiang, Jundan ; Zhang, Honghong ; Wang, Danfeng

BACKGROUNDPain and depression are common complications in patients with advanced cancer, which significantly affects their quality of life and survival. Dysregulation of the JAK/STAT3 pathway in the central nervous system is associated with pain and brain inflammatory disorders, but its role in bone cancer pain (BCP) remains unclear. This study aimed to investigate the specific role of the JAK/STAT3 pathway in the amygdala in BCP.METHODSA BCP rat model was established by intratibial injection of MRMT-1 carcinoma cells. Pain behavior was assessed using the mechanical withdrawal threshold, while depression-like behavior was assessed using the sucrose preference and forced swim test. Changes in inflammatory factors and related protein expression levels in the amygdala were detected using western blotting, immunofluorescence, and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of intra-amygdala injections of a lentivirus targeting retinoic acid-related orphan receptor γt (RORγt) (LV-shRORγt), nifuroxazide (a STAT3 antagonist), and colivelin (a STAT3 agonist) were evaluated.RESULTSRats with BCP demonstrated increased microglial activation in the amygdala. Rats experiencing RORγt knockout in the amygdala showed reduced microglial activation levels. Nifuroxazide reduced Th17 cell differentiation, potentially alleviating pain and depression-like behaviors. To further explore the underlying relationship between the JAK/STAT3 pathway and Th17 cells, LV-shRORγt and a STAT3 agonist were co-administered. The inhibitory effect of LV-shRORγt counteracted the STAT3 agonist's active effects.CONCLUSIONSOur study showed that targeting JAK/STAT3 signaling alleviated pain- and depression-like behaviors in rats with BCP by inhibiting Th17 cell differentiation.

100 Deals associated with Nifuroxazide

Login to view more data